mitoMAN
Senior Member
- Messages
- 629
- Location
- Germany/Austria
https://www.news-medical.net/news/2...related-MIS-C-in-children-suggests-study.aspx
"Finally, one patient with MIS-C was treated with a zonulin antagonist called larazotide to visualize the effects on SARS-CoV-2 antigens in the blood and the overall clinical response. The child treated with larazotide had multiple medical problems and had a history of severe COVID-19 with respiratory failure and cardiac arrest. One month later, the patient developed signs of MIS-C, failing to show improvement with steroids nor intravenous immunoglobulins (IVIG). High viral RNA titers were present in the stool, as well as spike antigens in plasma even two weeks after these agents were started.
Treatment with larazotide led to a dramatic reduction in viral antigens, inflammatory markers and clinical parameters, compared to the ineffectiveness of either steroids or IVIG."
"It also serves as a 'proof of concept that zonulin antagonism directly reduces SARS-CoV-2 antigenemia with abatement of the cytokine storm and subsequent clinical improvement in a single patient.'
Larazotide has a high safety margin and is undergoing phase 3 trials for the treatment of resistant celiac disease, an inflammatory bowel condition. Its use led to a 90% fall in spike antigen levels in the blood, with significant improvement in inflammation, fever and general illness."
"Finally, one patient with MIS-C was treated with a zonulin antagonist called larazotide to visualize the effects on SARS-CoV-2 antigens in the blood and the overall clinical response. The child treated with larazotide had multiple medical problems and had a history of severe COVID-19 with respiratory failure and cardiac arrest. One month later, the patient developed signs of MIS-C, failing to show improvement with steroids nor intravenous immunoglobulins (IVIG). High viral RNA titers were present in the stool, as well as spike antigens in plasma even two weeks after these agents were started.
Treatment with larazotide led to a dramatic reduction in viral antigens, inflammatory markers and clinical parameters, compared to the ineffectiveness of either steroids or IVIG."
"It also serves as a 'proof of concept that zonulin antagonism directly reduces SARS-CoV-2 antigenemia with abatement of the cytokine storm and subsequent clinical improvement in a single patient.'
Larazotide has a high safety margin and is undergoing phase 3 trials for the treatment of resistant celiac disease, an inflammatory bowel condition. Its use led to a 90% fall in spike antigen levels in the blood, with significant improvement in inflammation, fever and general illness."